Skip to main content

Advertisement

Table 3 Option value and participation premiums to induce donation (US$ of 2013)

From: An analysis of economic incentives to encourage organ donation: evidence from Chile

  Wage Option Participation Savings
Value Premium Costs Costs + QALY
(1) (2) (3) (4) (5)
(i) Prevalence rate of 14% for kidney chronic disease
Mean 625 18,321 5974 32,295 163,897
Percentiles
 1 40 1169 381 49,447 181,049
 5 102 2987 974 47,629 179,231
 10 160 4675 1524 45,941 177,543
 25 245 7169 2338 43,447 175,049
 50 367 10,754 3506 39,862 171,464
 75 612 17,923 5844 32,693 164,295
 90 1213 35,538 11,587 15,078 146,680
 95 1995 58,443 19,056 (7827) 123,775
 99 4078 119,488 38,960 (68,872) 62,730
(ii) Individuals in fourth and fifth category have a non-functioning kidney
Mean 625 44,398 32,051 6218 137,820
Percentiles
 1 40 2833 2045 47,783 179,385
 5 102 7239 5226 43,377 174,979
 10 160 11,330 8179 39,286 170,888
 25 245 17,374 12,542 33,242 164,844
 50 367 26,060 18,813 24,556 156,158
 75 612 43,434 31,355 7182 138,784
 90 1213 86,121 62,170 (35,505) 96,097
 95 1995 141,626 102,239 (91,010) 40,592
 99 4078 289,560 209,031 (238,944) (107,342)
  1. (a) In panel (i), the option value is computed per percentile weighting the VSI by 0.14 and the VSL by 0.001. In panel (ii), the option value is computed per percentile weighting the VSI by 0.10 and the VSL by 0.003. (b) Negative values (costs) in parentheses. (c) Participation premiums are computed subtracting the reservation price in Table 2 to the option value. (d) Savings in costs consider only savings to the health system. Benefits in QALY consider gains of improving the quality of life of patients after receiving an organ (see Harrison et al. (2010) and references therein)